<div id="readability-page-1">11:58 AM EDT, 05/15/2026 (MT Newswires) -- Danaher ( DHR ) could see about 6% revenue growth in 2027, driven by a rebound in bioprocess demand trends and improving end markets, RBC Capital Markets said.RBC's channel checks indicate robust demand trends for bioprocess consumables and expanding equipment funnels, according to the note. This positions Danaher ( DHR ) to benefit from the sector recovery as bioprocessing represents more than 25% of the company's revenue, the investment firm said in a Thursday note.Danaher ( DHR ) is also working to close menu gaps in its Beckman Coulter business and sees continued improvement in its molecular diagnostics segment amid a recovering underlying diagnostics market. The company could see further growth upside from its Masimo (MASI) acquisition, which is expected to close in the second half of 2026, RBC added.RBC Capital Markets resumed coverage on Danaher ( DHR ), with an outperform rating and a $200 price target.Shares of Danaher ( DHR ) were down 1.1% in Friday afternoon trading.Price: 162.75, Change: -1.79, Percent Change: -1.09 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

丹納赫

2 倍做多納斯達克生物技術 ETF - ProShares

紐交所高增長板生物技術指數 ETF - First Trust

標普健康醫療設備 ETF - SPDR

生物科技 ETF - VanEck Vectors

標普生物技術 ETF - SPDR

動態生物技術與基因組 ETF - Invesco

美國醫藥設備 ETF - iShares

標普生物技術 3 倍做多 - Direxion

RBC 資本市場預測，丹納赫（Danaher，股票代碼：DHR）在 2027 年可能實現 6% 的收入增長，這得益於生物處理需求的反彈和市場的改善。該公司指出，生物處理耗材和設備的需求強勁。丹納赫還在解決其貝克曼庫爾特（Beckman Coulter）業務中的不足，並預計其收購馬西莫（Masimo）將帶來增長。儘管股價下跌 1.1% 至 162.75 美元，RBC 仍恢復了對該公司的覆蓋，給予 “跑贏大盤” 的評級，並設定 200 美元的目標價

Danaher Seen on Path to Growth Reacceleration on Bioprocess Recovery, RBC Says

fidelity

加拿大皇家銀行

麥斯莫醫療

RBC 表示，丹納赫在生物工藝恢復的推動下被視為重新加速增長